LivaNova PLC (LIVN) LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
Sector: Electromedical & Electrotherapeutic Apparatus
Industry: Medical - Devices
LivaNova PLC NASDAQ:LIVN Healthcare · Medical - Devices
AH Close $80.90 +0.00% vs close
AH Close $80.90 +0.00% vs close
All Press Release SEC Filings News
Press Release
Neuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova’s VNS Therapy for Drug-Resistant Epilepsy
The journal Neuromodulation published full 36-month results from the CORE-VNS study of LivaNova's VNS Therapy in drug-resistant epilepsy, showing a 76% median reduction in seizure frequency with durable, increasing benefit over time.
At 36 months, 16% of participants achieved complete seizure freedom, 64% achieved at least a 50% seizure reduction, and seizure-related hospitalizations fell 73%, with no new safety concerns identified.
The 531-participant analysis across 61 sites in 16 countries is the largest long-term real-world evaluation of contemporary VNS Therapy, strengthening the evidence base behind LivaNova's epilepsy franchise.
• 2d ago AI analysis › Press Release
LivaNova to Present at UBS, Wolfe, Stifel, and Jefferies Healthcare Conferences in November
LivaNova announced its Executive Leadership Team will present fireside chats at four November healthcare conferences hosted by UBS, Wolfe Research, Stifel, and Jefferies.
Sessions run Nov. 9 through Nov. 17 and will be webcast via the company's website, with replays available within 24 hours.
The release contains no financial results, guidance, or new operational disclosures; it is routine investor-event scheduling.
• 4d ago AI analysis › Press Release
LivaNova to Announce Third-Quarter 2026 Results
LivaNova PLC will release its third-quarter 2026 results and host a conference call on Wed., Nov. 4, 2026, at 8 a.m. Eastern Time.
The audiocast will be available at www.livanova.com/events, with a telephone dial-in and online pre-registration also offered, and a replay posted to the investor site afterward.
This is a scheduling notice only and contains no financial results or guidance; the actual earnings data will arrive with the November 4 release.
• 1mo ago AI analysis › Press Release
LivaNova to Present at Morgan Stanley and Baird Healthcare Conferences in September
LivaNova will present at two September healthcare conferences in New York City: the Morgan Stanley 24th Annual Global Healthcare Conference on Mon., Sept. 14 and the Baird 2026 Global Healthcare Conference on Tues., Sept. 15.
CEO Vladimir Makatsaria, CFO Alex Shvartsburg, and Chief Strategy and Corporate Development Officer Philip Kowalczyk will participate in a fireside chat at Morgan Stanley, while Chief Innovation Officer Ahmet Tezel joins Makatsaria and Shvartsburg at the Baird event.
Webcasts will be accessible via livanova.com/events with replays posted within 24 hours; the release contains no financial results, guidance changes, or new business developments.
• 1mo ago AI analysis › SEC Filing ⚠ 6
LIVN: 10-Q · periodic report
LivaNova reported Q2 2026 net revenue of $390.6 million, up 10.8% year over year, with net income of $108.6 million and diluted EPS of $1.93 versus $0.50 a year ago. Both segments grew double digits, with Cardiopulmonary up 11.2% on Essenz Perfusion System demand and Neuromodulation up 10.1% on broad-based VNS Therapy growth.
The headline profit was flattered by a one-time discrete tax benefit of $95.4 million (EUR 81.8 million) from an Italian tax ruling on the deductibility of the SNIA environmental liability expense. Underlying operating income actually slipped to $49.5 million from $54.2 million as the company added $11.4 million to its 3T Heater-Cooler litigation provision, which now stands at $23.1 million.
The balance sheet strengthened, with cash of $516.6 million and total debt cut to roughly $293.5 million after a $95.9 million Term Facilities payoff in January. The March 2026 FDA PMA approval for the aura6000 sleep apnea system triggered a $60.5 million ImThera milestone payment in June, with commercial ramp spending now flowing through R&D.
The key overhang remains the SNIA environmental litigation, carried at $385.0 million (EUR 337.8 million), with the Milan Court of Appeal scheduling a December 9, 2026 hearing for the parties to discuss a possible out-of-court resolution. No assurance of settlement was provided in the filing.
SEC 10-Q • 2mo ago AI analysis › Press Release ● Major ⚠ 1
LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
LivaNova reported second-quarter 2026 revenue of $390.6 million, up 10.8% year-over-year, with adjusted diluted EPS of $1.26 driven by growth in Cardiopulmonary and Epilepsy segments.
The company raised full-year 2026 guidance, projecting revenue growth of 8% to 9% on a constant-currency basis and adjusted EPS of $4.30 to $4.40, up from prior ranges.
Strategic highlights include a long-term agreement with Thermo Fisher Scientific to secure oxygenator components and a favorable tax ruling resulting in a $95.4 million benefit, though adjusted free cash flow guidance was lowered to support capacity investments.
• 2mo ago AI analysis › Press Release
LivaNova to Announce Second-Quarter 2026 Results
LivaNova PLC scheduled the release of its second-quarter 2026 financial results for Wednesday, Aug. 5, 2026.
The company will host a conference call to discuss the results at 8 a.m. Eastern Daylight Time on the same day.
Access details for the live audiocast and subsequent replay are available on the Investors section of the LivaNova website.
• 4mo ago AI analysis › Press Release
LivaNova Demonstrates 84.5% Cumulative Response Rate with PolySync Programming in OSPREY Study for Obstructive Sleep Apnea
LivaNova presented new data from the OSPREY study showing that its PolySync programming algorithm increased the cumulative AHI response rate to 84.5% for OSA patients treated with pHGNS, up from a 65% baseline response rate.
The substudy demonstrated that reprogramming non-responders with simultaneous-contact stimulation converted the majority into responders, with PolySync slated for integration into commercial products.
Building on the FDA approval received in March, the company plans to submit a PMA supplement for a next-generation MRI-compatible OSA device in the second half of 2026.
• 4mo ago AI analysis › SEC Filing
LIVN: 8-K · proxy statement
LivaNova PLC reported the results of its 2026 Annual General Meeting held on June 10, 2026, where shareholders adopted all ten proposals presented. The board of directors was re-elected in full, with each of the eleven directors receiving overwhelming support, typically exceeding 99% of votes cast in favor.
Shareholders also approved the U.S. Say on Pay advisory vote, ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor, and authorized the company to repurchase up to 10% of its issued ordinary shares. The filing confirms routine corporate governance activities with no contested elections or significant dissenting votes.
SEC 8-K • 4mo ago Press Release
LivaNova Appoints Anne Liddy as Chief Legal Officer
LivaNova has appointed Anne Liddy as its new Chief Legal Officer, effective August 31.
Liddy joins from Hologic, Inc., where she served as General Counsel, bringing over two decades of experience in healthcare legal and compliance matters.
She will oversee the global legal and compliance function and serve as a member of the Executive Leadership Team.
• 4mo ago AI analysis › Press Release
LivaNova Appoints Stefano Folli to Lead its Cardiopulmonary Business Unit
LivaNova appointed Stefano Folli as President of its Cardiopulmonary business unit, effective June 1, succeeding Franco Poletti who is retiring.
Folli, formerly Executive Vice President at Philips, will oversee the nearly $800 million Cardiopulmonary segment, which includes the Essenz Perfusion System.
He will partner with Poletti through July to ensure a smooth transition before assuming full responsibility on August 1.
• 5mo ago AI analysis › Press Release ● Critical
LivaNova Reports First-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance
LivaNova reported Q1 2026 revenue of $362.3 million, up 14.3% year-over-year, with adjusted diluted EPS of $0.98.
The company raised its full-year 2026 revenue growth guidance to 7.0%-8.0% and adjusted EPS guidance to $4.20-$4.30, reflecting strong execution.
Additionally, LivaNova received FDA premarket approval for its aura6000 System to treat obstructive sleep apnea, marking a key regulatory milestone.
• 5mo ago AI analysis › 
